Rongtai health(603579) 太平洋证券·2025-04-25 14:10Investment Rating - The report maintains a "Buy" rating for the company, Rongtai Health (603579) [1][8] Core Views - The company has shown a recovery in gross margin in Q1 2025, with a focus on the DeepHealth smart health model, automotive scenarios, and new forms of robotic hands, indicating potential for growth [1][8] - The company reported a total revenue of 1.597 billion yuan in 2024, a decrease of 13.92%, and a net profit of 192 million yuan, down 5.31% [4][5] - The Q1 2025 revenue was 395 million yuan, a decline of 1.41%, with a net profit of 44 million yuan, down 29.97% [4][5] Summary by Sections Financial Performance - In 2024, the company's revenue from massage chairs and small massage appliances was 1.518 billion yuan and 51 million yuan, respectively, with year-on-year declines of 14.05% and 28.64% [5] - Domestic and overseas revenues in 2024 were 652 million yuan and 923 million yuan, respectively, with declines of 20.17% and 10.25% [5] - The gross margin improved from 29.66% in Q4 2024 to 32.54% in Q1 2025, an increase of 2.88 percentage points [6] - The net profit margin decreased from 11.33% in Q4 2024 to 11.14% in Q1 2025 [6] Product and Market Development - The company is expanding into automotive massage products and has established a subsidiary for this purpose, collaborating with Faurecia China [7] - A partnership with Shanghai Jiao Tong University aims to enhance product capabilities through AI [7] - The company anticipates growth in overseas markets, particularly in Europe and the Middle East, with a strong performance in cross-border e-commerce [5][7] Future Projections - The company expects net profits of 200 million yuan in 2025, 221 million yuan in 2026, and 246 million yuan in 2027, with corresponding EPS of 1.13, 1.25, and 1.39 yuan [8] - The projected revenue growth rates for 2025, 2026, and 2027 are 3.10%, 10.50%, and 10.70%, respectively [8]